AstraZeneca Vietnam has been honoured with the British Chamber of Commerce (BritCham)’s first-ever 50th Anniversary Recognition award. The award acknowledges the company’s unwavering commitment to innovation, sustainability, and its profound impact on Vietnam’s healthcare sector. This recognition comes as part of the celebration of the 50 years of bilateral relations between the UK and Vietnam.
Mr. Nitin Kapoor, Chairman and General Director of AstraZeneca Vietnam and Asia Area Frontier Markets, said: “As a global biopharmaceutical company with British-Swedish heritage and nearly three decades accompanying Vietnam’s health system, we are driven by a shared purpose to build a healthier future and make a lasting impact through innovation and sustainability. We are immensely proud to contribute to the UK-Vietnam partnership and will continue to bring the advances of Britain’s life sciences industry to create positive change for the people in Vietnam.”
AstraZeneca was ranked number 1 in Invention of Idea Pharma’s 2023 Pharmaceutical Innovation and Invention Index, and has been the leader in terms of industry-sponsored clinical trials in Vietnam. Out of the $360 million (8.5 trillion VND) that AstraZeneca has committed to invest in Vietnam until 2030, a significant amount has been dedicated to research and development to further strengthen the country’s research capabilities and increase patients’ early access to new medicines. AstraZeneca’s innovative medicines have improved the lives of millions of Vietnamese patients with non-communicable diseases, while its COVID-19 vaccine played an important role in Vietnam’s fight against the pandemic.
In addition, AstraZeneca Vietnam’s commitment to sustainability is evident in its initiatives to promote access to healthcare, protect the environment, and uphold ethics and transparency. As part of the company’s impactful partnerships with the Ministry of Health and healthcare organisations, AstraZeneca has run various community investment programmes to promote disease awareness, prevention, and early detection.
In order to support Vietnam’s sustainable development and net zero strategy, AstraZeneca recently announced a 50 million USD investment into Vietnam to plant 22.5 million trees over the next five years, as part of the company’s global AZ Forest programme. This project will help to restore Vietnam’s forests and landscapes, allowing biodiversity to flourish, and providing sustainable livelihoods for over 17,000 smallholder farmers, alongside other co-benefits for the economy, communities, and environment.
This award adds to the extensive list of recognition that AstraZeneca has received in its long-standing collaboration with Vietnam. The company’s contributions to vaccine diplomacy, the fight against COVID-19, and advancements in cancer treatment and disease awareness programmes have earned certificates of merit from the Prime Minister and Minister of Health. Additionally, AstraZeneca has been recognised as one of Vietnam’s Top 100 Best Places to Work for four consecutive years.
Note to editors:
The GREAT Awards programme, organised annually by BritCham, recognises excellence and rewards organisations and individuals who have made significant contributions to the business environment in Vietnam. A wide cross section of sectors are represented including education, technology, banking, health, and science, to name but a few.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
AstraZeneca Vietnam’s signature programmes
Over the last three decades in Vietnam, AstraZeneca has run several impactful programmes in collaboration with the Ministry of Health and healthcare partners to promote disease awareness, prevention, and early detection. Amongst them are the Healthy Lung Programme to improve the quality of outpatient management of asthma, COPD and lung cancer; Young Health Programme to prevent and reduce NCD risk behaviours amongst young people; and CaReMe programme to transform the cardiovascular-renal-metabolic care ecosystem.
AstraZeneca is also cooperating with the World Economic Forum, London School of Economics, and Health Strategy and Policy Institute – Vietnam Ministry of Health, in the Partnership for Health System Sustainability and Resilience (PHSSR), to holistically reinforce the Vietnamese health system so that it can guard against future risks.
Press release distributed by EloQ Communications.